Chinook Therapeutics, Inc.
108 articles about Chinook Therapeutics, Inc.
-
Chinook Therapeutics Announces Upcoming Data Presentations and Investor Conference Call at the 59th European Renal Association (ERA) Congress
5/2/2022
Chinook Therapeutics, Inc. today announced upcoming data presentations at the 59th ERA Congress from May 19 – 22, 2022, both virtual and live in Paris, France.
-
Chinook Therapeutics to Present at the 2022 Bloom Burton & Co. Healthcare Investor Conference
4/25/2022
Chinook Therapeutics, Inc. announced that Chinook management is scheduled to present and participate in 1x1 meetings at the 2022 Bloom Burton & Co. Healthcare Investor Conference in Toronto, Ontario on Monday, May 2, 2022 at 10:00 am ET.
-
Chinook Therapeutics Announces Initiation of Phase 1 Healthy Volunteer Trial of CHK-336, a First-in-Class LDHA Inhibitor to Treat Hyperoxalurias
4/12/2022
Chinook Therapeutics, Inc. (NASDAQ: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced that dosing has been initiated in a phase 1 clinical trial evaluating CHK-336 in adult healthy volunteers.
-
Chinook Therapeutics, IgA Nephropathy Foundation and Komodo Health Collaborate to Provide Nephrologists with Support and Information to Help Reduce Barriers to Diagnosis and Care
4/5/2022
Chinook Therapeutics, Inc., the IgA Nephropathy Foundation and Komodo Health announced an outreach initiative leveraging data and technology to drive awareness of Immunoglobulin A nephropathy and engage key medical providers at nephrology practices across the U.S.
-
Chinook Therapeutics to Present at the 21st Annual Needham Virtual Healthcare Conference
4/5/2022
Chinook Therapeutics, Inc. today announced that Eric Dobmeier, president and chief executive officer of Chinook Therapeutics, is scheduled to present and participate with management in 1x1 meetings at the 21st Annual Needham Virtual Healthcare Conference on Tuesday, April 12, 2022 at 3:00 pm ET.
-
Chinook Therapeutics Announces Appointment of Dr. Mahesh Krishnan to its Board of Directors
3/21/2022
Chinook Therapeutics, Inc. today announced the appointment of Mahesh Krishnan, M.D., M.P.H., M.B.A., FASN to its Board of Directors.
-
Chinook Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2021 Financial Results
3/17/2022
Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today provided a business update and reported financial results for the fourth quarter and year ended December 31, 2021.
-
Chinook Therapeutics to Present at Oppenheimer’s 32nd Annual Healthcare Conference
3/8/2022
Chinook Therapeutics, Inc. announced that Chinook management is scheduled to participate in a virtual fireside chat and 1x1 meetings at Oppenheimer’s 32nd Annual Healthcare Conference on Tuesday, March 15, 2022 at 10:40 am ET.
-
Chinook Therapeutics Announces Upcoming Presentations at 4th Annual Chronic Kidney Disease Drug Development Summit
2/22/2022
Chinook Therapeutics, Inc. (NASDAQ: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced upcoming presentations at the 4th Annual Chronic Kidney Disease Drug Development (CKD) Summit in Boston from March 1 - 3, 2022.
-
Chinook Therapeutics Announces Upcoming Encore Presentations at ISN World Congress of Nephrology 2022
2/18/2022
Chinook Therapeutics, Inc. today announced upcoming presentations at the ISN World Congress of Nephrology 2022 from February 24 – 27, 2022.
-
Chinook Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare Conference
2/9/2022
Chinook Therapeutics, Inc. announced that Chinook management is scheduled to participate in a virtual fireside chat at the 11th Annual SVB Leerink Global Healthcare Conference on Wednesday, February 16, 2022 at 10:00 am ET.
-
Chinook Therapeutics Announces New Employment Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Feb 04, 2022
2/4/2022
Chinook Therapeutics, Inc., a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, announced that the Compensation Committee of the Company’s Board of Directors approved a new employment inducement grant of stock options to purchase 150,000 shares of common stock with a grant date of January 31, 2022 to one new employee.
-
BioSpace Movers & Shakers, Jan. 28
1/28/2022
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers. -
Chinook Therapeutics Announces Appointment of Charlotte Jones-Burton, M.D., M.S. as Senior Vice President of Product Development and Strategy
1/24/2022
Chinook Therapeutics, Inc. today announced the appointment of Charlotte Jones-Burton, M.D., M.S. as senior vice president of product development and strategy.
-
Chinook Therapeutics to Present at Upcoming Investor Conferences - Jan 04, 2022
1/4/2022
Chinook Therapeutics, Inc., a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, announced that Chinook management is scheduled to participate in the following upcoming virtual investor conferences.
-
Chinook Therapeutics Receives Orphan Drug Designation from European Commission for Atrasentan for Treatment of Primary IgA Nephropathy
12/14/2021
Chinook Therapeutics, Inc. today announced the European Commission has granted orphan drug designation for atrasentan for the treatment of primary IgA nephropathy (IgAN).
-
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
-
Chinook Therapeutics Announces Formation of SanReno Therapeutics, a Joint Venture to Develop Kidney Disease Therapies in China
11/30/2021
Chinook Therapeutics, Inc. announced the formation of SanReno Therapeutics, a joint venture with an investor syndicate led by Frazier Healthcare Partners and Pivotal bioVenture Partners China, to develop, manufacture and commercialize kidney disease therapies in the People’s Republic of China, Hong Kong, Macau, Taiwan and Singapore.
-
Chinook Therapeutics to Present at Upcoming Investor Conferences - Nov 17, 2021
11/17/2021
Chinook Therapeutics, Inc., a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, announced that Chinook management is scheduled to participate in the following upcoming virtual investor conferences:
-
Chinook Therapeutics Announces Closing of $183.5 Million Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
11/15/2021
Chinook Therapeutics, Inc. announced the closing of its upsized underwritten public offering of 9,538,572 shares of its common stock at a price to the public of $14.00 per share, which includes the exercise in full of the underwriters’ option to purchase an additional 1,710,000 shares of its common stock.